The metabolic profile of cancer cells can be used to identify biomarkers and develop therapies associated with cancer outcome.
In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the National Cancer Institute discovered an association between the oncometabolite 2-hydroxyglutarate (2-HG) levels, DNA methylation patterns and breast cancer prognosis.
AdvertisementThe authors identified a breast cancer subtype with high levels of 2-HG, and a district DNA methylation pattern that was associated with reduced survival. This breast cancer subtype was common in African-American breast cancer patients, who as a group have a high prevalence of aggressive breast cancers. This study indicates that evaluation of 2-HG along with DNA methylation may be a useful biomarker for breast cancer diagnosis and prognosis.
P New Flu Vaccine can Reduce Risk of Serious Illnesses in Children Joint Task Force Comes Out With New Guideline That Updates Definition of Severe Asthma M
You May Also Like